alexa Fed and Fasting Bioequivalence Study for Two Formulatio
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Fed and Fasting Bioequivalence Study for Two Formulations of Bosentan 125 Mg Tablets in Healthy Colombian People

Vargas M1*, Bustamante C2 and Villarraga EA3

1Pharmacology Unit Universidad De La Sabana, Bogotá-Colombia

2Universidad La Sabana, Bogotá - Colombia

3Pharmacology Unit Universidad De La Sabana, Bogotá-Colombia

*Corresponding Author:
Vargas M
Dentist, Pharmacologist, Scientific Director
Pharmacology Unit Universidad
De La Sabana, Bogotá-Colombia
Tel: 861 5555
E-mail: [email protected]

Received Date: April 23, 2015; Accepted Date: June 25, 2015; Published Date: July 02, 2015

Citation: Vargas M, Bustamante C, Villarraga EA (2015) Fed and Fasting Bioequivalence Study for Two Formulations of Bosentan 125 Mg Tablets in Healthy Colombian People. J Bioequiv Availab 7:210-215. doi:10.4172/jbb.1000242

Copyright: © 2015 Vargas M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



This is a pharmacokinetic study of two formulations containing Bosentan 125 mg, in order to compare the bioavailability between the Test product (Bosentan produced by Tecnoquímicas S.A. laboratory, Colombia) and the Reference product (Tracleer® produced by Actelion Pharmaceuticals) in fasting and fed conditions, in order to state the bioequivalence between them. With this purpose, an open label, four periods, two randomized sequences, crossover, with single pre- and fed 125 mg dose study was performed in 30 healthy volunteers, with an 8-day washout period between each period and a collection of 14 plasma samples between 0 and 24 hours. Identification and evaluation of Bosentan in plasma was carried out by ultra-high-performance liquid chromatography-tandem mass spectrometry UHPLC/MS/MS as analytical method. Based on the European and FDA bioequivalence research guidelines, the Confidence Interval (CI) falls within the allowed ranges for the Bioequivalence and Interchangeability Statement of the Tecnoquímicas S.A. product with the Reference product. Both formulations had similar pharmacokinetic parameters in each studied condition, fed and fasted. Moreover, an increase in the amount of active pharmaceutical ingredient is evident in fed conditions.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version